Moderna, Inc. (MRNA)
| Market Cap | 60.44B |
| Revenue (ttm) | 803.40M |
| Net Income (ttm) | -747.06M |
| Shares Out | 381.33M |
| EPS (ttm) | -1.96 |
| PE Ratio | n/a |
| Forward PE | 8.06 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $160.50 |
| Previous Close | $162.84 |
| Change ($) | -2.34 |
| Change (%) | -1.44% |
| Day's Open | 147.82 |
| Day's Range | 143.56 - 163.47 |
| Day's Volume | 29,647,889 |
| 52-Week Range | 46.13 - 189.26 |
Why this biotech analyst has a hold rating on Moderna
CNBC's "Closing Bell" team discusses the biotech sector after Moderna reported its latest earnings results with Michael Yee of Jefferies.
Moderna (MRNA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Moderna Inc. (NASDAQ: MRNA) shares gapped down Thursday and have since gained back some ground. Moderna reported first-quarter earnings Thursday of $2.84 per share, beating the estimate of $2.39.
12:20pm: Pharmaceutical stocks fall The Dow was up 162 points, 0.5%, to 34,393 at midday. The Nasdaq was ticked down 7 points to 13,576, and the S&P 500 picked up 12 points, 0.3%, to 4,180.
Is (MRNA) Outperforming Other Medical Stocks This Year?
Moderna posts first-ever quarterly profit in Q1
Yahoo Finance's Anjalee Khemlani reports Moderna's first quarter and the outlook through 2021. Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://youtu.be/gx-OzwHpM9k
U.S. backs COVID-19 vaccine patent waiver
Yahoo Finance's Brian Sozzi, Myles Udland, Julie Hyman, and Anjalee Khemlani discuss what the vaccine patent waiver means for Moderna's business.
Moderna, Inc. (NASDAQ: MRNA). uniQure N.V.
Even bigger profits could be on the way, despite worries about international waivers of the biotech's patents for its COVID-19 vaccine.
The US has backed a proposal first put forward by India and South Africa for a temporary waiver on COVID-19 vaccine patents. “The administration believes strongly in intellectual property protections, b...
The shares of Moderna Inc (NASDAQ:MRNA) are careening this morning, down 10.3% to trade $146.03, and brushing off the company's first-ever profit.
Moderna (MRNA) delivered earnings and revenue surprises of 39.22% and -1.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
The drug manufacturer announced its first profitable first quarter.
Moderna CEO Stephane Bancel said Thursday the company expects more variants of the coronavirus will emerge in the coming months.
Moderna's (MRNA) Q1 earnings exceeded analyst expectations, while revenue missed estimates. It was the company's first profitable quarter.
Moderna Stock Drops As Q1 Sales Fails To Meet Expectations; Anticipates $19.2B In FY21 Product Sales
Moderna Inc (NASDAQ: MRNA) reports Q1 EPS of $2.84, a turnaround from EPS loss of $0.35 a year ago, beating the consensus estimate of $2.39. However, Q1 revenues of $1.9 billion compared to $8 million a...
Moderna Inc (NASDAQ:MRNA) and Pfizer Inc. (NYSE:PFE) had a double dose of good news regarding their COVID-19 vaccines. Moderna said that its tweaked jab was successful in neutralising the South African ...
Moderna posts EPS beat, revenue miss for the first quarter
CNBC's Meg Tirrell reports on Moderna's first-quarter earnings results as well as the most recent data the company released about its Covid vaccine trials for teenagers.
Moderna Inc raised its 2021 sales forecast for its COVID-19 vaccine by 4.3% to $19.2 billion on Thursday, reflecting demand from countries looking to return to normalcy through rapid inoculation.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna reports first quarter fiscal year 2021 financial results and provides business updates.
The Biden administration is backing international plans to suspend intellectual property protections.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces new supply agreement with Switzerland for 7 million booster vaccine doses in 2022 and option for additional 7 million doses.
Some of the stocks that may grab investor focus today are: Moderna Inc (NASDAQ: MRNA) reported the effectiveness of its COVID-19 vaccine against variants in an internal study. The company is also expect...
If enacted, such a move would hit the smaller vaccine makers particularly hard.
Two types of booster proved efficacious against a pair of more threatening coronavirus variants.
Pharmaceutical stocks are facing a major new threat.
Moderna releases new information on booster shots
Yahoo Finance's Anjalee Khemlani reports the latest update on Moderna's booster shot studies. Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://youtu.be/gx-OzwHpM9k
Moderna (MRNA) closed at $162.84 in the latest trading session, marking a -6.19% move from the prior day.
Moderna Co-founder on Boosters Against Variant Strains
May.05 -- Moderna's mid-stage trials show its booster shots were effective against strains of the coronavirus that emerged from Brazil and South Africa. Co-founder Noubar Afeyan speaks exclusively with ...
Moderna said its booster dose increased neutralizing antibody responses against the original virus as well as B.1.351 and P.1 variants.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces positive initial booster data against SARS-CoV-2 variants of concern.
Moderna (MRNA) reports Q1 earnings before market open on May 6. Will the company finally report a profit after years of losses as COVID-19 vaccine sales soar?
Probably not, but the study could benefit another vaccine maker.
Ocugen may be able to handle one of the biggest challenges facing vaccine makers.
The biotech just provided a big clue that sales are poised to skyrocket.
Moderna to Supply 500 Million Covid-19 Vaccine Doses to Covax
May.04 -- Moderna co-founder and Chairman Noubar Afeyan discusses the company's agreement to provide 500 million doses of its Covid-19 vaccine to Covax, increased vaccine production, and testing of a lo...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces expansion of its Manufacturing Technology Center in Massachusetts.
They could be just getting started, too.
Investors cheered the vaccine maker's latest move to help end the pandemic.
Final Trades: Uber, ViacomCBS, Moderna & more
The "Halftime Report" traders give their top picks to watch for the second half.
Investors are likely to focus on any updated outlook for Modena's (MRNA) authorized coronavirus vaccine and developmental progress with new COVID-19 vaccine candidate on the first-quarter earrings call.
Covax, the World Health Organization's vaccine sharing program, is in dire need of vaccine doses. Wealthier countries have faced calls to step up.
Moderna Inc (NASDAQ: MRNA) has announced an agreement with vaccine promoter Gavi to supply up to 500 million doses of its COVID-19 vaccine to boost the global vaccination effort. Still, most of the ship...
They'll give us a snapshot of the future.
Both vaccines do an impressive job of providing protection against COVID-19. But Moderna's is much easier to get from production facilities into patients' arms.
About MRNA
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeu... [Read more...]
| Industry Biotechnology | IPO Date Dec 7, 2018 |
| CEO Stephane Bancel | Employees 1,300 |
| Stock Exchange NASDAQ | Ticker Symbol MRNA |
Financial Performance
In 2020, Moderna's revenue was $803.40 million, an increase of 1,234.34% compared to the previous year's $60.21 million. Losses were -$747.06 million, 45.3% more than in 2019.
Analyst Forecasts
According to 16 analysts, the average rating for Moderna stock is "Buy." The 12-month stock price forecast is 175.50, which is an increase of 9.35% from the latest price.